Please login to the form below

Not currently logged in
Email:
Password:

Keynote-024

This page shows the latest Keynote-024 news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

In recently published long-term data from the phase 3 KEYNOTE-024 trial, Keytruda reduced the risk of death by 38% versus chemotherapy at the five-year time point among NSCLC ... In addition, another advanced, PD-1-positive NSCLC monotherapy study of

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...